Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2 randomised, dose-finding, multicentre study Saranya Sridhar , Arnel Joaquin , Matthew Bonaparte , Agustin Bueso , Anne-Laure Chabanon , Aiying Chen , Roman M. Chicz , David Diemert , Brandon J. Essink , Bo Fu , Nicole A. Grunenberg , Helene Janosczyk , Michael C. Keefer , Doris M. M. Rivera , Ya Meng , Nelson L. Michael , Sonal S. Munsiff , Onyema Ogbuagu , Vanessa N. Raabe , Randall Severance , Enrique Rivas , Natalya Romanyak , Nadine G. Rouphael , Lode Schuerman , Lawrence D. Sher , Stephen R. Walsh , Judith White , Dalia von Barbier , Guy de Bruyn , Richard Canter , Marie-Helene Grillet , Maryam Keshtkar-Jahromi , Marguerite Koutsoukos , Denise Lopez , Roger Masotti , Sandra Mendoza , Catherine Moreau , Maria Angeles Ceregido , Shelly Ramirez , Ansoyta Said , Fernanda Tavares-Da-Silva , Jiayuan Shi , Tina Tong , John Treanor , Carlos A. Diazgranados , Stephen Savarino The Lancet Infectious Diseases（2022）
Key words
recombinant protein vaccine, immunogenicity, sars-cov, dose-finding
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
